Clinical Trial Update: A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating liposomal doxorubicin with or without olaratumab (IMC-3G3) in platinum-refractory or resistant advanced ovarian cancer; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Neoplasms

Drugs mentioned

• Olaratumab (olaratumab)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-04-14